Trials / Completed
CompletedNCT02426359
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Qurient Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Q301 Cream | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-01-01
- Completion
- 2016-05-01
- First posted
- 2015-04-24
- Last updated
- 2016-12-06
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02426359. Inclusion in this directory is not an endorsement.